Medicon Village-based Saga Diagnostics acquired by Roche for $595M
We congratulate SAGA Diagnostics on its acquisition by the Swiss healthcare group Roche, which is acquiring the company for up to $595 million and will integrate it into its affiliate Foundation Medicine. Founded as a spin-out from Lund University, SAGA Diagnostics has developed a world-leading platform for ultra-sensitive cancer monitoring using liquid biopsy-based MRD analysis.
Foundation Medicine, an independent affiliate of Roche, intends to expand its monitoring portfolio by integrating SAGA Diagnostics’ tumour-informed MRD platform following the completion of the acquisition. The transaction, subject to customary regulatory approvals, is expected to close by Q3 2026, after which the platform will be fully incorporated into Foundation Medicine’s offering.